Valo Therapeutics Aims to Improve Personalized Immunotherapy With a New Tech
Valo Therapeutics Oy (ValoTx), the developer of antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines against cancer and infectious disease, announced the exclusive licensing of intellectual property rights for the PeptiCHIP technology, developed at the University of Helsinki, Finland. This technology is expected to speed up identification of tumor antigens (including the group of neoantigens) for the development of new cancer immunotherapies using Valo’s existing technologies.
Topics: Tools & Methods